NL300248I1 - Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren. - Google Patents

Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.

Info

Publication number
NL300248I1
NL300248I1 NL300248C NL300248C NL300248I1 NL 300248 I1 NL300248 I1 NL 300248I1 NL 300248 C NL300248 C NL 300248C NL 300248 C NL300248 C NL 300248C NL 300248 I1 NL300248 I1 NL 300248I1
Authority
NL
Netherlands
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Application number
NL300248C
Other languages
English (en)
Other versions
NL300248I2 (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300248(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL300248I1 publication Critical patent/NL300248I1/nl
Publication of NL300248I2 publication Critical patent/NL300248I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL300248C 1996-06-25 2006-11-27 Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren. NL300248I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (2)

Publication Number Publication Date
NL300248I1 true NL300248I1 (nl) 2007-02-01
NL300248I2 NL300248I2 (nl) 2007-03-01

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300248C NL300248I2 (nl) 1996-06-25 2006-11-27 Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.

Country Status (37)

Country Link
US (3) US6465504B1 (nl)
EP (1) EP0914118B1 (nl)
JP (1) JP3541042B2 (nl)
KR (1) KR100616378B1 (nl)
CN (1) CN1146415C (nl)
AP (1) AP1127A (nl)
AR (1) AR007479A1 (nl)
AT (1) ATE226435T1 (nl)
AU (1) AU718037B2 (nl)
BG (1) BG64248B1 (nl)
BR (1) BR9709973A (nl)
CA (1) CA2255951C (nl)
CY (2) CY2429B1 (nl)
CZ (1) CZ291470B6 (nl)
DE (3) DE69716602T2 (nl)
DK (1) DK0914118T3 (nl)
ES (1) ES2187785T3 (nl)
FR (1) FR06C0049I2 (nl)
GE (1) GEP20084355B (nl)
HK (1) HK1020530A1 (nl)
HU (1) HU226232B1 (nl)
IL (1) IL127212A0 (nl)
LT (1) LTC0914118I2 (nl)
LU (1) LU91291I2 (nl)
MY (1) MY129541A (nl)
NL (1) NL300248I2 (nl)
NO (3) NO317180B1 (nl)
NZ (1) NZ333308A (nl)
OA (1) OA10946A (nl)
PL (1) PL194758B1 (nl)
PT (1) PT914118E (nl)
RU (1) RU2208010C2 (nl)
SI (1) SI0914118T1 (nl)
SK (1) SK284319B6 (nl)
TR (1) TR199802693T2 (nl)
TW (1) TW533205B (nl)
WO (1) WO1997049395A1 (nl)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
US20080139480A1 (en) * 2003-12-19 2008-06-12 Bruemmendorf Tim H Combination Of (A) N--4-(3- Pyridyl)-2-Pyrimidine-Amine And (B) At Least One Hypusination Inhibitor And The UseThereof
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
RU2404776C2 (ru) * 2005-01-28 2010-11-27 Новартис Аг ПРИМЕНЕНИЕ ПИРИМИДИЛАМИНОБЕНЗАМИДОВ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, ЧУВСТВИТЕЛЬНЫХ К МОДУЛЯЦИИ АКТИВНОСТИ КИНАЗЫ Тie-2
WO2006084683A1 (en) * 2005-02-10 2006-08-17 Novartis Ag Methods for improving drug disposition
KR20080003933A (ko) * 2005-05-31 2008-01-08 노파르티스 아게 철이 발병에 관여하는 간질환의 치료
RU2008119410A (ru) * 2005-10-19 2009-11-27 Новартис АГ (CH) Диспергируемые таблетки, включающие деферасирокс
WO2007051773A1 (en) * 2005-11-01 2007-05-10 Novartis Ag Method of scintigraphy
BRPI0711385A2 (pt) * 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
MX2008014837A (es) 2006-05-23 2008-12-01 Novartis Ag Metodo para el tratamiento de hemocromatosis hereditaria.
CL2007002026A1 (es) * 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
EP2049108A1 (en) * 2006-08-04 2009-04-22 Novartis AG Treatment of endocrine dysfunction using iron chelators
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
AU2007327585B2 (en) * 2006-11-29 2011-09-29 Novartis Ag Polymorphic forms of deferasirox ( ICL670A)
WO2008094617A2 (en) * 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of deferasirox
MX2009012375A (es) * 2007-05-14 2009-12-01 Novartis Ag Uso de quelante del hierro para el tratamiento del infarto de miocardio.
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
CZ301873B6 (cs) * 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
WO2010032489A1 (ja) 2008-09-22 2010-03-25 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
RU2011142173A (ru) 2009-03-19 2013-04-27 ЛОС-АНДЖЕЛЕС БАЙОМЕДИКАЛ РИСЕРЧ ИНСТИТЬЮТ ЭТ ХАБОР-ЮСиЭлЭй МЕДИКАЛ СЕНТР Вакцинные композиции и способы лечения мукоромикоза и других грибковых заболеваний
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
WO2011070560A1 (en) 2009-12-07 2011-06-16 Mapi Pharma Hk Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
US8703203B2 (en) 2010-07-08 2014-04-22 Ratiopharm Gmbh Oral dosage form of deferasirox
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
EP2621471A2 (en) * 2010-10-01 2013-08-07 Cipla Limited Pharmaceutical composition comprising deferasirox
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
EP2664333B1 (en) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
WO2013053904A1 (en) 2011-10-14 2013-04-18 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
RU2659034C2 (ru) * 2013-03-06 2018-06-27 Биокон Лимитед Способ получения деферазирокса
TWI625136B (zh) * 2013-03-08 2018-06-01 諾華公司 祛鐵斯若（ｄｅｆｅｒａｓｉｒｏｘ）之口服配方
MX2015015553A (es) * 2013-05-10 2016-06-17 Cipla Ltd Composicion farmceutica de dosis baja.
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
PT2946771T (pt) 2014-05-20 2019-06-27 Sanovel Ilac Sanayi Ve Ticaret As Formulação de comprimido dispersível em água compreendendo deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CR20170143A (es) 2014-10-14 2017-06-19 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
TN2017000375A1 (en) 2015-03-10 2019-01-16 Aduro Biotech Inc Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
WO2017068090A1 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
EP3429562A1 (en) 2016-03-17 2019-01-23 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
NO986024L (no) 1998-12-21
EP0914118A1 (en) 1999-05-12
CA2255951C (en) 2006-10-10
NO2018014I1 (no) 2018-04-17
DE69716602T2 (de) 2003-06-26
CY2007005I1 (el) 2010-07-28
ES2187785T3 (es) 2003-06-16
FR06C0049I1 (nl) 2007-03-09
US6465504B1 (en) 2002-10-15
IL127212A0 (en) 1999-09-22
KR20050098029A (ko) 2005-10-10
US6596750B2 (en) 2003-07-22
NO2006017I2 (no) 2011-07-04
RU2208010C2 (ru) 2003-07-10
SK284319B6 (sk) 2005-01-03
NL300248I2 (nl) 2007-03-01
PT914118E (pt) 2003-02-28
FR06C0049I2 (fr) 2007-04-27
DE122007000020I2 (de) 2010-12-30
CN1146415C (zh) 2004-04-21
BG103003A (en) 1999-09-30
HK1020530A1 (en) 2000-05-12
MY129541A (en) 2007-04-30
CZ427298A3 (cs) 1999-03-17
SK178598A3 (en) 1999-06-11
BR9709973A (pt) 1999-08-10
HUP9903111A2 (hu) 2000-01-28
LU91291I9 (nl) 2018-12-27
SI0914118T1 (en) 2003-04-30
WO1997049395A1 (en) 1997-12-31
ATE226435T1 (de) 2002-11-15
BG64248B1 (bg) 2004-07-30
AP9801407A0 (en) 1998-12-31
AP1127A (en) 2002-12-06
JP2000507601A (ja) 2000-06-20
CZ291470B6 (cs) 2003-03-12
NO986024D0 (no) 1998-12-21
CY2429B1 (en) 2004-11-12
TR199802693T2 (xx) 1999-05-21
JP3541042B2 (ja) 2004-07-07
EP0914118B1 (en) 2002-10-23
TW533205B (en) 2003-05-21
NO2018014I2 (no) 2018-11-19
DE69716602D1 (de) 2002-11-28
AU718037B2 (en) 2000-04-06
LU91291I2 (fr) 2007-01-29
NZ333308A (en) 2000-05-26
DE122007000020I1 (de) 2007-05-24
HUP9903111A3 (en) 2000-06-28
DK0914118T3 (da) 2003-02-24
PL330119A1 (en) 1999-04-26
AR007479A1 (es) 1999-10-27
HU226232B1 (en) 2008-07-28
NO2006017I1 (no) 2006-12-18
US20030069273A1 (en) 2003-04-10
CY2007005I2 (el) 2018-12-12
GEP20084355B (nl) 2008-04-29
PL194758B1 (pl) 2007-07-31
NO317180B1 (no) 2004-09-06
LTPA2007001I1 (lt) 2018-06-25
OA10946A (en) 2003-02-27
KR100616378B1 (ko) 2006-08-28
US6723742B2 (en) 2004-04-20
LTC0914118I2 (lt) 2018-12-27
AU3262997A (en) 1998-01-14
CN1223579A (zh) 1999-07-21
CA2255951A1 (en) 1997-12-31
US20030203954A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
NL300248I2 (nl) Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
NL350032I1 (nl) Pyrazool-4-yl-benzoylderivaten de toepassing ervan als herbiciden.
DE59608798D1 (de) Endoparasitizide mittel
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
DE69636837D1 (de) 1,2,4-benzotriazinoxid-formulierungen
BR9708948A (pt) 1,3 - Benzodioxois substituídos
ITPN940023A0 (it) Mobile metallico per comunita'
ES1029825Y (es) Hucha perfeccionada.
ES1029171Y (es) Armario metalico perfeccionado.
IT1283187B1 (it) "elettrovalvola."
IT1274643B (it) Costruzione rapida "isodomus".
ITSV960001V0 (it) Dispositivo erogatore-distributore di sostanze in polvere o grnuli, in particolare saliera.
ES1031907Y (es) Parasol perfeccionado.
ES1030370Y (es) Rodamiento perfeccionado.
BR9711721A (pt) Paraherquamidas e marcfortinas de 24,25-epoxi e 25-metileno
ES1032570Y (es) Nuevo pijama perfeccionado.
ES1038556Y (es) "nuevo atril".
ES1034207Y (es) Cojunto de rodadura perfeccionado.
ES1036635Y (es) Buscapersonas perfeccionado.
ES1027222Y (es) Puerta metalica perfeccionada.
ES1028415Y (es) Puerta metalica perfeccionada.